398
Participants
Start Date
June 30, 2021
Primary Completion Date
May 31, 2028
Study Completion Date
June 30, 2028
Tri-lipid skin barrier cream (Epiceram)
The aim is to compare the effect of proactive sequential skin care, including the twice daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone proprionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
Fluticasone propionate Cream 0.05%
Proactive use of fluticasone proprionate cream for inflammation of the skin, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
Standard of Care
Participants' eczema will be managed by their primary physician, i.e. standard of care with routine reactive topical products for atopic dermatitis flares.
Cincinnati Children's Hospital Medical Center, Cincinnati
University of Chicago, Chicago
Division of Pediatric Allergy and Clinical Immunology, National Jewish Health, Denver
Sean N. Parker Center for Allergy & Asthma Research at Stanford University, Palo Alto
• King's College London and Guy's and St. Thomas' NHS Foundation Trust, UK, London
National Jewish Health
OTHER
University of Chicago
OTHER
Children's Hospital Medical Center, Cincinnati
OTHER
Harvard School of Public Health (HSPH)
OTHER
Stanford University
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
King's College London
OTHER
Guy's and St Thomas' NHS Foundation Trust
OTHER
Kari Nadeau, MD, PhD
OTHER